Innovation Acta News
2024
-
Oct4-5
Almost a year (1st December 2023) after starting the project Eco2Wine (Natural microbial interactions in winemaking-associated ecosystems as a tool to foster wine innovation) the consortium met in Stellenbosch, South Africa, on 4 & 5 October 2024.
Most of the beneficiaries, supervisors, co-supervisors, and doctoral candidates attended the meeting in person, while a few joined the meeting online.
The doctoral candidates' involvement in the event was vital as each presented their research plan and secondments, offering an excellent opportunity for discussion and planning collaborations. Speakers for each work package presented an overview of the activities and Innovation Acta provided an overview of administrative management tasks and presented activities with a focus on website development and maintenance.
-
Oct1-2
The fourth annual HDM-FUN meeting was held on October 1-2, 2024 nicely hosted by UZ Leuven. INNOVATION ACTA participated in the event, providing updates on project management, dissemination, communication activities, upcoming deadlines, and reporting requirements.
The meeting featured productive discussions and offered PhD students the opportunity to present their research. It concluded with a mini-symposium on the immunology of severe infections, including lectures from HDM-FUN principal investigators.
-
Oct1-2
We are pleased to announce the successful completion of our 2nd T-FITNESS Annual Meeting, which brought together all the partners of the Consortium coordinated by the Leibniz Institute for Immunotherapy. The event was organised by Innovation Acta and held in Sitges, Spain, on 1-2 October 2024.
The meeting fostered rich discussions and collaboration, significantly enhancing our shared knowledge. We were also pleased to welcome our new partner, Prof. Roman Jerala from the Kemijski inštitut (Slovenia), to the consortium. We extend our sincere gratitude to all attendees for their active participation, and a special thanks go to our advisory board members for their invaluable insights and guidance, which will play a crucial role in shaping our future initiatives. We look forward to continuing our collaboration and supporting this great consortium in advancing innovation!
-
Sept20
The fourth annual LiverScreen meeting was held on September 20, 2024, at Padova University Hospital. INNOVATION ACTA attended the meeting and shared updates on Project management, deadlines and reporting activities.
The annual meeting was organised in the context of the International Meeting on MASLD, organized by the University of Padova (Prof. Paolo Angeli and Prof. Robert Vettor) from September 20 to 21 2024 in Padova.
In conjunction with the MASLD Meeting, a LiverScreen Symposium was organized to showcase the project's contributions to the field. The symposium covered the following key topics:
- The impact of innovative technology (Laurent Castera, Paris)
- Screening of liver disease: is it cost effective? (Miquel Serra Burriel, Zurich)
- Best screening strategies in the general population (Maja Thiele, Odense)
- The LiverScreen project (Pere Gines, Barcelona)
-
Jul12
geneTIGA and T-FITNESS projects win fundings to include new partners from the Widening countries
GeneTiga and T-FITNESS projects, of which Innovation Acta is partner, have been recently granted by the EU Commission to include new partners and expertise from the widening countries. The two projects, supported by Innovation Acta, applied to the Hop On facility call with the aim to synergize with research groups from Genos (Croatia) and Kemijski Institut (Slovenia), respectively, and further boost the impact of the original projects. The EU introduced Widening to the framework research programme in 2014 under Horizon 2020, with the goal of helping countries lagging in research and innovation performance to close the gap with Europe’s top performers. This year Greece dominates the list of top performers for winning Horizon Europe funding among the 15 EU Widening countries, with six out of the top 10 places taken by the country’s institutions. While these measures are performing well in helping widening countries to strengthen their participation in transnational research and innovation processes, and promote networking and access to excellence, the imbalance between Widening countries and Europe’s top performers still persists and the EU’s next framework research programme FP10 is expected to continue funding projects aimed at bridging Europe’s research and innovation gap.
-
Jul12
The 2025 Work Programme of the European Research Council has been adopted!
-
JUN6-7
Successful 1st Annual Meeting of the IMMUTOL project
We recently attended the 1st Annual Meeting of the IMMUTOL (Advanced Antigen-Specific Dendritic Cells Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases) project. The meeting took place on the 6th and 7th of June 2024 and had over 30 participants. It was hosted and organized by the team of Assistant Professor Jordi Martorell López at the Department of Chemical Engineering and Materials Science in Barcelona, Spain, with support from Innovation Acta. The event provided a comprehensive update on the project's progress. Speakers for each work package shared updates, and participants engaged in a roundtable discussion led by relevant partners. During the meeting, we provided an overview of administrative management tasks and presented the activities focused on communication, dissemination, exploitation, and citizen engagement together with ADEMTO.
Photo of participants
First day of the meeting
-
APR29-30
2nd Annual General Assembly of Innovative Health Initiative (IHI) GUIDE.MRD Consortium
The Innovative Health Initiative (IHI) GUIDE.MRD Consortium partners met for the 2nd Annual General Assembly hosted by the coordinating institution at the Universitätsklinikum Hamburg Eppendorf (UKE), from 29-30 April 2024 and organized with the support of Innovation Acta S.r.l. (INN-ACTA).
After a warm welcome to the beautiful city of Hamburg by the Project Coordinator Klaus Pantel (UKE) and the Project Leader Bristol Myers Squibb (BMS) represented by Luigi Ravagnan, the progress on all work packages was presented by the work package (WP) leads and co-leads.
Moreover, a fruitful plenum discussion with all participants on current challenges and mitigation strategies as well as the next steps within the consortium was held.
Over 30 participants from the 25 partners engaged in very productive discussions on the results reached by the consortium in the first 12 months.
We would like to thank all partners involved!
-
APR16-17
Successful DoC Kick-Off Meeting Marks the Beginning of exTra Doctoral Network Project!
We have attended the DoC kick-off meeting of extra, a doctoral network project focused on Extracorporeal Photopheresis (ECP) in solid organ transplantation. The meeting, organized by Innovation Acta, was held in Regensburg on 16-17 April and brought together project partners for 2 days filled with insightful discussions and promising presentations from 11 talented doctoral candidates.
Over the next 36 months, these doctoral candidates will serve as the driving force behind exTra project, leveraging their expertise to generate groundbreaking data and insights. Their work will be instrumental in advancing understanding of ECP and paving the way for its translation into clinical practice.
-
APR1
EIC Women Leadership Programme: Open Call – for female researchers and aspiring female leaders
The European Innovation Council (EIC) is pleased to announce the launch of the 5th cohort of the EIC Women Leadership Programme (EIC WLP). Building on the success from the previous editions, this cohort, running from April - June 2024, will offer EIC female researchers and aspiring female leaders the tools and support to enhance their leadership skills.
more info
-
MAR20
Next Event - Interreg Europe
Call open from 20 March to 7 June 2024
Program Manual here
Sign-up for the online edition of Europe, let's cooperate interregional cooperation forum, which will take place on 20th March 2024 live from Antwerp. Registration is open!
-
MAR21-22
LIVERAIM Kick-off Meeting
The LIVERAIM project kicked off on March 21st and 22nd with representatives from all of our 27 partners, involving researchers, SMEs, biotechnology companies and the pharmaceutical industry to start a public-private collaboration of 25 million € invested by the Innovative Health Initiative and industry for the development of a biomarker-based platform for early diagnosis of chronic liver disease to enable personalised therapy.
The two-day meeting was organised by Nicola van Berckel from FRCB-IDIBAPS with the support of Innovation Acta and gently hosted by Prof. Pere Ginès at the Faculty of Medicine and Health Sciences of the University of Barcelona (Spain). The first day was organised in the form of an open event to discuss about the global burden of chronic liver diseases highlighting the gaps, the challenges, and successes in tackling this issue. In the second day, the meeting gathered more deeply on LIVERAIM project by presenting workplan and objectives and scheduling the upcoming activities. INNOVATION ACTA attended the meeting and shared updates on Project management, deadlines and reporting activities.
Representatives of IHI Research Programme, industry, State Government of Catalunia, and high representatives of FRCB-IDIBAPS, Hospital Clinic, and University of Barcelona were invited to the meeting to give high relevance of the project at different level and stakeholders.
First day speakers 
LIVERAIM consortium members
-
MAR12
GLYCO-N Kick-off Meeting
The GLYCO-N partners met in Naples on 12th March 2024 for the Kick off meeting to get to know each other, and plan future project activities and the recruitment of Doctoral Candidates. The event was hosted by the Department of Chemical Sciences, University of Napoli Federico II and nicely organised by Prof Antonio Molinaro with the support of Innovation Acta. Innovation Acta attended the meeting and shared updates on Project management, recruitment process and Project website.
-
FEB27
PROTO First Annual meeting
The PROTO partners met on Salzburg on 27th February 2024 for the First project Annual meeting to share the advancements achieved in the first year and discuss on the challenges ahead. As a partner delivering project management and communication activities INNOVATION ACTA attended the meeting and shared updates on Project management, reporting activities, progresses on the Communication activities and Project website. At the heart of PROTO collaborative effort is the mission to address inflammation, the pivotal factor in the progression of Osteoarthritis. The consortium comprises leaders in various fields such as omics, cellular immunology, molecular biomarkers, physiology, biomechanics, and stem cell biology. Together, PROTO is actively engaged in groundbreaking clinical studies, notably with advanced therapy medicinal products. A significant milestone on horizon is the initiation of a first-in-human phase I/IIa study. This study focuses on patients with moderate knee osteoarthritis and investigates the promising anti-inflammatory PLX-PAD cell therapy. Simultaneously, PROTO is implementing an innovative, high-level personalized sensor- and app-based training intervention for patients in the pre-stage of Osteoarthritis. This multifaceted approach underscores partners’ commitment to addressing the complex facets of this debilitating condition. Integral to PROTO project are cutting-edge ancillary studies aimed at defining immune-mediated mechanisms both in and ex vivo. Additionally, the initiative seeks to identify a spectrum of biomarkers, including immunologic, metabolic, genetic, and MRI-based morphologic markers. This comprehensive approach enables precise patient stratification, a crucial step towards more effective and personalized interventions.
-
JAN25-26
NECESSITY Fifth General Assembly
The NECESSITY project held its annual General Assembly with representatives from all of our 25 partners, including both from industry and academia. We were also honored to have the indispensable Patient Advisory Group (PAG) representatives among us. The two-day meeting was hosted by our industry partner, GSK in Stevenage (London, UK). The main objectives of the two days were to facilitate discussions within the NECESSITY Project Consortium on key advances and innovative approaches in the fields of immunology and rheumatology. More importantly, the meeting aimed to address any challenges that arose and to propose solutions for the smooth progression of the project. Exciting new methodologies and results were presented for the stratification of patients based on tissue and blood biomarkers. Additionally, we delved into an emerging approach in computational biology to evaluate the pathophysiology of Sjogren’s disease. Furthermore, we witnessed the first examples of the scientific community using STAR.
-
JAN12
THRIVE Kick off meeting
The European Union’s THRIVE project (Tumor host interactions in liver cancer for childhood and adults) held its kick-off meeting on Friday, 12 January 2024. Thirty-five people attended the meeting, which took place in the Esteve Auditorium of the Esther Koplowitz Centre, where IDIBAPS’ headquarters are located.
Members and participants of the kick-off meeting of the THRIVE project
More information about the project here
2023
-
NOV20-22
1st TOLERATE Annual Meeting – 20-22 November 2023, Amsterdam
The 1st Annual Meeting for the TOLERATE project has been held in Amsterdam from the 20th to 22nd of November. The event has been organised by the project partner Sanquin with the support of Innovation Acta. The 3-days meeting included the progress meeting with presentations from all the fellows, and three different training courses on scientific and transferable skills.
-
NOV14-15
geneTIGA Annual Meeting in Enchanting Rome on 14th -15th November
On 14 and 15 November 2023 INN-ACTA organized the First Annual meeting of geneTIGA project in Italy.
geneTIGA is a Research and Innovation Action funded under Horizon Europe that aims to develop a safe and efficient cell therapy based on genome-edited T cells with redirected specificity to sustainably combat IgA nephropathy (IgAN). geneTIGA specific cell therapy approach is also suitable for other diseases with selective B-cell pathogenesis, such as IgA myeloma and rheumatoid arthritis, but as a blueprint also for diseases of other Ig classes.
We had the pleasure of gathering all consortium members from Germany, Spain, Norway, Denmark, UK and Switzerland, in the breathtaking city of Rome for a very productive and inspiring meeting. The meeting provided a valuable opportunity for us to discuss about the work accomplished and progresses achieved in the past year and about the new challenges ahead. The exchange of ideas was lively, with each member contributing their unique perspectives and expertise to the conversation.
Rome, with its rich history and cultural significance, provided the perfect backdrop for fostering a sense of unity among consortium members.
We look forward to leveraging the insights gained during this meeting to propel our project forward. -
OCT22-23
GUIDE.MRD First face-to-face meeting on 22nd and 23rd of October in Madrid
The GUIDE.MRD consortium partners met for the first face-to-face annual meeting hosted by Dr. Núria Malats at CNIO - Spanish National Cancer Research Centre, in Madrid, Spain, from 22-23 October 2023 and organized with the support of Innovation Acta S.r.l.
During the first day first day the monthly Steering Committee meeting took place in presence, chaired by the Academic Coordinator, Prof. Klaus Pantel, Universitätsklinikum Hamburg Eppendorf and the Project Leader, Bristol Myers Squibb, followed by a networking evening hosted by CNIO with fruitful discussions on the GUIDE.MRD project and most recent data from ESMO 2023.
The second day was opened by welcoming remarks from the Academic Coordinator and a presentation on the hosting partner CNIO. Thereafter, the Work Package leaders Ellen Heitzer (Medical University Graz, Austria, WP2) and Claus Lindbjerg Andersen (Aarhus University Hospital, Denmark, WP3) as well as clinical study leaders Matthias Löhr (Karolinska Institute, Sweden, WP3) and Jeroen Hiltermann (University Medical Center Groningen, The Netherlands, WP3) presented the most recent data and progress of the project.
Over 40 participants from the 22 partners engaged in very productive discussions on the results reached by the consortium in the first 6 months as well as some of the main challenges and opportunities. It was also noted how input from patients has been incorporated since this early phase of the project through our partners The Synergist, Lung Cancer Europe, Digestive Cancers Europe and the project's Patients Advisory Board, especially in relation to the first three clinical trials. -
OCT23
The B-specific Kick-Off meeting, 23rd October 2023 in Leiden
The B-specific consortium led by Amanda Foks (Leiden Academic Centre for Drug Research, Leiden University, The Netherlands) successfully kicked-off the project B-specific (B-cell related gene and protein markers with prognostic and therapeutic value for CVD). The event was held on the 23rd of October 2023 at the Faculty Club (Academy Building) in Leiden (The Netherlands). Thanks to European Innovation Council (EIC) (Grant Nr. 101115159) for supporting the research to discover new biomarkers and therapeutic targets for atherosclerosis.
-
OCT01
B-specific project starts on the 1st of October 2023
We are glad to announce that the B-specific project, funded by the European Innovation Council under the 2022 Pathfinder Challenge call will officially start on the 1st of October 2023. During the next four years, the international consortium coordinated by Leiden University (The Netherlands) will focus on the discovery of novel biomarkers of cardiovascular disease to accelerate the impact of these in clinical practice. Innovation Acta, as part of the Consortium, will assist the administrative bodies of the Partners’ institutions and will provide support to communication activities. The Kick-off meeting will be held on the 23rd of October 2023 in Leiden (The Netherlands).
-
SEP18-19
T-FITNESS meeting in Capri
On the 18th and 19th of September, the T-FITNESS consortium met in the beautiful island of Capri for the first annual meeting. This EIC Pathfinder grant aims to explore bold ideas for radically new technologies. In particular, T-FITNESS aims to revolutionize current T cell immunotherapies by developing an innovative platform to overcome T cell exhaustion. During the meeting, the partners discussed the remarkable progress made within just one year of the project's inception and exchanged valuable insights regarding the challenges ahead.
-
SEP01
01 September 2023 exTra Project officially started!
exTra is a Doctoral Network funded under Horizon Europe Programme. exTra Consortium is a research network of leading European scientists from academia and industry, experts in clinical transplantation, immunology, pharmaceutical development and medical device manufacture to address key questions on extracorporeal photopheresis (ECP) through a coordinated, interdisciplinary effort. exTra proposes 11 independent doctoral research projects with the ambition of providing its trainees with a comprehensive understanding of basic and translational immunology, especially relating to development and licensing of new immunotherapies. Through its research and training activities, the exTra project will contribute to scientific advancement and innovation in Europe, ultimately leading to societal and economic benefits stemming from clinical innovations in transplant immunotherapy and beyond. Innovation-Acta is Associated Partner of the Network for management, training and communication activities.
-
MAY-JUN30-1
INsTRuCT final meeting on 31st May and 1st June 2023 in Regensburg
INsTRuCT Network members from 13 beneficiaries, the 15ESRs, the associated industrial partners Sanofi, AstaZeneca, UCB Biopharma and InnovationActa, met in Regensburg for the final meeting. The meeting included outstanding presentations from all 15ESRs, now at the third year of their research work, who reported about their individual projects and achievements in the in the myeloid regulatory cell (MRC)-based therapy research. A Networking session for ESR and commercial partners was part of the programme. INsTRuCT is funded under Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860003. The project combines excellence in basic, preclinical and translation research with an outstanding programme of scientific education and practical training for early stage researchers, who are driving critical advancement in the field.
-
MAY24-25
IMMUTOL Kick off meeting on 24th and 25th of May 2023 in Milan
The IMMUTOL Consortium, led by Silvia Gregori (San Raffaele Telethon Institute for Gene Therapy– SR-Tiget) successfully kicked-off the project "Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases". The hybrid event was held on 24th and 25th of May at Fondazione Telethon, Milano (Italy). Innovation Acta organized and joined the meeting. Thanks to EU Horizon Europe (Grant Agreement Nr.: 101080562) for supporting fast-tracking the development and validation of an Advanced Therapy Medicinal Product based on engineered dendritic cells to treat patients with immune-mediated diseases with an unmet medical need, in particular multiple sclerosis.
-
MAY1
GUIDE.MRD project starts on 1st May 2023
On May 1st 2023 just started GUIDE.MRD, a five-year Innovative Health Initiative project. GUIDE.MRD is a consortium of leading academics, technology companies, pharmaceutical companies, patient organizations, and experts in multi-stakeholder engagements. Innovation Acta, as part of the Consortium, will provide support to the administrative management of the project, and to communication activities. GUIDE.MRD will tackle the critical questions by developing reference standards for circulating tumor DNA (ctDNA) diagnostics, clinically validate promising ctDNA diagnostics and develop data to guide the use of multi-modal therapies with a noninvasive diagnostic test. With robust engagement with regulatory authorities, payers and importantly patients themselves, we will develop recommendations and guidelines based on objective data to use ctDNA diagnostics to guide multimodal therapy selection to improve patient outcomes. GUIDE.MRD Kick off meeting will be held online on 29th – 30th June 2023
-
MAY1
IMMUTOL project starts on 1st May 2023
We are thrilled to announce that 1st of May 2023 is the official start of IMMUTOL. For the next four years, in the frame of this Research and Innovation Action, the main goal will be to fast-track the development and validation of an advanced therapeutic medicinal product, aimed to treat patients with immune-mediated diseases. IMMUTOL will develop a more potent and durable treatment for autoimmune diseases with an unmet medical need, in particular Multiple Sclerosis.
The consortium gathers experts and institutions from different sectors, from research institutions and academia, patients’ association to hospitals and corporate SME. Innovation Acta, as part of the Consortium, will provide support to the administrative management of the project, and to communication activities.
The Kick-off meeting will be held on 24th and 25th of May 2023 in Milano (Italy). -
MAR1
PROTO Kick-off meeting 28th February-1st March 2023 in Berlin
We successfully kicked-off our PROTO consortium during these exciting two last days! Thanks to EU Horizon Europe (Grant Nr. 101095635) for supporting our endeavour to prevent, early diagnose and treat osteoarthritis.
-
JAN1
PROTO project officially started!
January 1st marks the official start of PROTO, a five -year international project coordinated by Charité - Universitätsmedizin Berlin, Germany. The Kick-off meeting will be held in Berlin on 28 February-1st March 2023. PROTO will develop novel interventional strategies aimed at tackling the development and progression of osteoarthritis. The PROTO consortium gathers experts and institutions from different sectors, from academia to SMEs and patient organizations. They all focus on distinct and complementary steps in the clinical research on musculoskeletal diseases, from ATMP manufacturing and characterization, their application in the clinic, implementing biomarker analysis, metabolomics and genetic profiling and patient input and information. Innovation Acta is part of this great team and ambitious project’s goal.
2022
-
DEC21
Innovation Acta wishes you a relaxed Christmas time, Nice Holiday Season and a Happy, Healthy and Successful 2023!
-
DEC20
New EIC Work Programme
The new EIC Work Programme 2023 has been published. Main calls in 2023 are summarised below
-
OCT01
TOLERATE starts today!
October 1st marks the official start of TOLERATE, a Marie Skłodowska-Curie Doctoral Network (MSCA-DN) funded by the European Union Horizon Europe Programme. TOLERATE aims at training 8 Doctoral Candidates to acquire the skills to develop different innovative strategies to treat autoimmune diseases, to identify the most promising strategies or a combination of strategies, to setup clinical trials and to develop a roadmap to bring a novel therapeutic agent to the market. As Associated Partner, Innovation Acta will provide support to the administrative management of the project, and to communication activities.
-
SEP01
T-FITNESS project official start
September 1st marks the official start of T-FITNESS, a four-year international project coordinated by the Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany. T-FITNESS is one of 39 projects -out of 403 proposals- selected for funding by the European Innovation Council in the 2021 Pathfinder Challenge call. Innovation Acta will provide support to this great team and ambitious project’s goal aiming to revolutionize current T cell immunotherapies.
-
JUL22
The European Commission has recently launched a pilot evaluation process within the EIC Pathfinder programme under the so-called "Rebuttal Phase"
-
FEB16
StairwAI 1st Open Call
Artificial intelligence: the first call of the StairwAI project is now open.
StairwAI, is a European Union-funded project which aims to facilitate the engagement of low-tech companies in the AI4EU platform (a one-stop-shop for anyone looking for Artificial Intelligence (AI) knowledge, technology, tools, services, and experts) and the implementation of AI.
The project has now launched its first open call or funding opportunity for low-tech small and medium-sized companies (SMEs) that do not have immediate access or knowledge on AI techniques to improve their products, services, or value chains with the support of AI Experts and High Computing Cloud Providers.
-
FEB15
NextGenerationEU
NextGenerationEU: European Commission raises 5 billion in additional funds for recovery
With the first bond issue by syndication in 2022, the European Commission raised today an additional €5 billion in NextGenerationEU funds on behalf of the EU. Maturing on 6 July 2051, the 30-year bond, executed as an increase in an existing EU bond, brings the total funding raised under the programme to €78.5 billion. The successful placement of the Commission will help to boost Europe’s recovery from the COVID-19 pandemic.
-
FEB15
Ideas Powered for Business
Intellectual property: launch of the "Ideas Powered for Business" website, the new information hub for European SMEs
The European Intellectual Property Office (EUIPO) has created a centralised information hub for businesses interested in intellectual property aspects. With the new “Ideas Powered for Business” website, the EUIPO is intensifying efforts to help entrepreneurs, start-ups, and small to medium-sized enterprises (SMEs) to alleviate some of the challenges they face in relation to intellectual property (IP).
The platform offers information geared towards supporting SMEs and other stakeholders to develop their business strategy and accelerate business growth with a clear focus on IP and IP rights, such as a training area, a database of IP services, an events section, and other resources.
-
FEB09
EIC Work Programme 2022
The Commission adopted today the 2022 work programme of the European Innovation Council. It opens funding opportunities worth over €1.7 billion in 2022 for breakthrough innovators to scale up and create new markets, for example in quantum computing, new generation batteries and gene therapy. Launched in March 2021 as a major novelty of the Horizon Europe programme, the European Innovation Council has a total budget of over €10 billion between 2021 and 2027.
-
FEB09
Linee Guida per le iniziative PNRR
Sono state pubblicate le Linee Guida del Ministero della Salute e MUR per i prossimi bandi del Piano complementare al Piano Nazionale di Ripresa e Resilienza per le Iniziative di ricerca per tecnologie e percorsi innovativi in ambito sanitario e assistenziale e per l’Ecosistema innovativo della salute.
-
JAN18
Commission selects first EIC Transition projects to take breakthrough technologies from the lab into the real world
The European Innovation Council (EIC) has selected 42 projects following a first ever EIC Transition calls for proposals. Successful proposals, selected among 292 submitted, will receive altogether €99 million of EU funding.
-
JAN18
ERC-funded Research wins most of new eu innovation grants
25 out of 42 recipients of the European Innovation Council’s new “Transition” funding originated from research funded by the ERC. The new grants will help take breakthrough technologies from the lab into the real world.
-
JAN14
Open Mission Calls
EU Missions new work program of Horizon Europe: 122.38 million euros are allocated to the first calls of the Mission "Adaptation to Climate Change", which opened on 11 January 2022. The Mission aims to support regions and communities in their adaptation to climate change, including the development of risk assessments, pathways and demonstrators of large-scale innovative systemic solutions that are cost-effective.
Mission: Adaptation to climate change (calls detail)
EU Missions new work program of Horizon Europe: 119.37 million euros are allocated to the first calls of the Mission "Climate-Neutral and Smart Cities", which opened on 11 January 2022. Other topics will open on April 28, 2022. The Mission intends to invest in new urban planning and design for sustainable, resilient and climate neutral cities, to unlock the innovation potential of public transport as the backbone of urban mobility and to create districts of positive clean energy.
Mission: Climate neutral and smart cities (call details)
EU Missions new work program of Horizon Europe: 62 million euros are allocated to the first calls for the Mission "Soil health and food", opened on 22 December 2021. Funded projects will support the creation of living labs on soil health and the validation and definition of soil health indicators, as well as the creation of a new generation of soil consultants to guide landowners and land managers in implementing sustainable practices, as well as to guide authorities in decision making for a positive impact on soil health.
-
JAN14
EU Missions Cancer
EU Missions new work program of Horizon Europe: 125.65 million euros are allocated to the first calls of the "Cancer" Mission, open from 22 December 2021. The Mission intends to develop new methods and technologies in cancer screening and early diagnosis, establish measures for the quality of life, as well as understand the impact of risk factors and health determinants on cancer development and progression.
-
JAN12
Horizon Europe: Tackling diseases 2022
New call: Tackling diseases (Single Stage - 2022). This call aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”.
-
JAN12
Partnerships in Health 2022
New call: European partnership fostering a European Research Area (ERA) for health research. The call is part of Destination 2 - Living and working in a health-promoting environment which aims to promote sustainable and health-friendly living and working environments thanks to a better understanding of environmental, occupational, social and economic risk factors.
-
JAN10
JPIAMR 14th Call
JPIAMR is launching an international call for projects under the umbrella of the JPIAMR and within the framework of the ERA-NET JPIAMR-ACTION. The call Disrupting drug resistance using innovative design involves 27 funding organisations from 18 countries. The total estimated call budget is close to 19 million Euro.
-
JAN10
Open calls “LIFE”
New call: LIFE-2021-Preparatory Projects as part of the Programme for the Environment and Climate Action (LIFE) Call for proposals. The call is launched in accordance with the 2021-2024 Multiannual Work Programme2 and will be managed by the European Climate, Infrastructure and Environment Executive Agency (CINEA) (‘Agency’).
-
JAN10
PNRR Italian calls
Nuovo bando per gli ecosistemi dell’innovazione territoriali
La misura prevede un investimento complessivo di 1,3 miliardi di euro.
Nuovi bandi bandi per le infrastrutture di ricerca e per le infrastrutture tecnologiche di innovazione
La misura prevede un investimento complessivo di 1,58 miliardi di euro.
Interested in contributing to the development of the European or National Projects? Join us by filling our collaboration form to be involved in any new opportunity tailored to your interests:
